NCT04082325View on ClinicalTrials.gov

Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

September 24, 2020

Study Completion Date

September 24, 2020

Conditions
Healthy
Interventions
DRUG

Lu AF88434

Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).

DRUG

Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)

Oral solution

DRUG

Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)

Oral solution

DRUG

Placebo

Placebo to Lu AF88434 oral solution, single dose

Trial Locations (1)

Unknown

QPS, Groningen

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT04082325 - Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men | Biotech Hunter | Biotech Hunter